Net gamma exposure for Allogene Therapeutics Inc (ALLO) options was positive at the Nov 4, 2026 close, about $8.92K per 1% move in the stock. It has been positive on 20 of the last 20 trading days. With positive gamma, dealer hedging tends to lean against price moves, which can dampen swings.
Upgrade to unlock Gamma Flip, Gamma Profile, Call Wall, Put Wall, and multiple expiration dates.
Gamma Exposure by Strike
Showing results for ALLO, 2026-11-20(m), calls & puts
Gamma Exposure Stats
Showing results for ALLO, 2026-11-20(m), calls & puts
Net Gamma Exposure by Expiration
Showing results for ALLO, 2026-11-20(m), calls & puts. View all expiries
| Expiration | Net GEX | Call GEX | Put GEX | Call Wall | Put Wall | Gamma Flip |
|---|
ALLO Gamma Exposure FAQ
What is gamma exposure (GEX)?
Gamma exposure estimates how much stock option dealers must buy or sell to stay hedged for each 1% move in the underlying.
Is ALLO gamma exposure positive or negative?
Allogene Therapeutics net gamma exposure was positive on Nov 4, 2026, at $8.92K. It has been positive on 20 of the last 20 trading days.
How has ALLO gamma exposure changed recently?
Allogene Therapeutics net gamma exposure went from $11.31K on Oct 7, 2026 to $8.92K on Nov 4, 2026. See the ALLO gamma exposure history for a longer view.
What is Allogene Therapeutics Inc?
Allogene Therapeutics Inc is a clinical stage immuno-oncology company pioneering the development of genetically engineered allogeneic T cell product candidates for the treatment of cancer and autoimmune diseases.